Pfizer can Prevent Covid Hospitalization by 90%

Nearly, 90 percent of Covid hospitalizations can be prevented with Pfizer. However, the effectiveness of the vaccine against all SARS-COV-2 infections declined.

For at least six months, taking two doses of Pfizer-BioNTech (BNT162b2) is found to be 90 percent effective against Covid-19 hospitalisations for all variants, reveals a new study published in The Lancet.

However, effectiveness against //all SARS-COV-2 infections declined, falling from 88 per cent within one month after receiving two vaccine doses to 47 after six months, stressing the need for a booster dose.

COVID Hospitalization Risk Higher Among South Asians In UK
In the UK, people of South Asian origin are at an increased risk for testing positive with COVID-19 and also at increased risks of hospitalization, ICU admission, and death, said study published in The Lancet.

TOP INSIGHT

Vaccine effectiveness against delta variant infections at one month after two doses of BNT162B2 was 93% and fell to 53% after four months.

The joint study by Kaiser Permanente Southern California and Pfizer underscores the importance of improving Covid-19 vaccination rates worldwide and monitoring vaccine effectiveness to determine which populations should be prioritised to receive booster shots.

"In line with the recent FDA and CDC recommendations, considerations for booster shots should take global Covid-19 vaccine supply into account as people in many countries around the world have not yet received a primary vaccination series," said lead author Dr Sara Tartof from Kaiser's Department of Research and Evaluation.

The team analysed 34,36,957 electronic health records between December 4, 2020, and August 8, 2021, to assess BNT162b2 vaccine effectiveness against SARS-CoV-2 infections and Covid-19-related hospitalisation.

During the study period, 5.4 percent of people were infected with SARS-CoV-2. Among those who were infected, 6.6 percent were hospitalised. The average time since being fully vaccinated was between three to four months.

Vaccine effectiveness against delta variant infections at one month after two doses of BNT162B2 was 93 percent and fell to 53 percent after four months.

Effectiveness against other (non-delta) variants at one month after receiving two doses was 97 percent and declined to 67 percent after four months.

Effectiveness against delta-related hospitalisations remained high (93 percent) for the duration of the study period.

COVID Hospitalization Rate Among Young US Adults Highest, Say Sources
Among young American adults aged between 30 to 39, the recent COVID-19 hospitalization rate is the highest ever since the pandemic hit the US early last year.

Researchers did not observe a difference in waning between SAR-CoV-2 variant types. However, the authors note that because delta became the dominant strain in the middle of the study period, analyses with longer follow-up to measure the rate of waning for delta compared to other variants are warranted.

"Covid-19 infections in people who have received two vaccine doses are most likely due to waning and not caused by delta or other variants escaping vaccine protection," said Dr Luis Jodar, Senior Vice President and Chief Medical Officer, Pfizer Vaccines.

Source-IANS